Rockwell Medical (RMTI) Current Deferred Revenue (2010 - 2024)

Rockwell Medical has reported Current Deferred Revenue for 15 years, with the latest figure at $475000.0 in Q4 2024.

• For the quarter ending Q4 2024, Current Deferred Revenue rose 932.61% year-over-year to $475000.0; the trailing twelve-month figure through Dec 2024 stood at $475000.0 (up 932.61% YoY), and the FY2024 full-year result was $475000.0, up 932.61% from the prior year.
• Current Deferred Revenue for Q4 2024 stood at $475000.0, up from $46000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $10.7 million in Q3 2020, with the low at $46000.0 in Q3 2023.
• Historically, Current Deferred Revenue has averaged $3.1 million across 5 years, with a median of $2.2 million in 2020.
• Annual changes were most pronounced in 2022 — Current Deferred Revenue surged 1346.0% — and 2023, when it plunged 99.32%.
• Rockwell Medical's Current Deferred Revenue stood at $2.2 million in 2020, then jumped by 275.03% to $8.2 million in 2021, then plunged by 78.78% to $1.7 million in 2022, then slumped by 97.34% to $46000.0 in 2023, then surged by 932.61% to $475000.0 in 2024.
• The last three Current Deferred Revenue figures came in at $475000.0 (Q4 2024), $46000.0 (Q3 2024), and $46000.0 (Q2 2024), per Business Quant data.